Short-term teriparatide treatment does not affect NT-proBNP, a marker of cardiac disease

Research output: Contribution to journalJournal articleResearchpeer-review

Maria Ellegaard, Peter Schwarz, Ann Caroline Hansen, Jens Faber, Henrik Vestergaard

Teriparatide (Parathyroid hormone (PTH) 1-34) has been shown to increase bone mineral density (BMD) and reduce the risk of vertebral fractures when given intermittently. In contrast primary hyperparathyroidism (PHPT) is associated with increased bone loss. Moreover an increased occurrence of cardiovascular disease (CVD) is seen in PHPT patients. The N-terminal fragment of the pro-peptide of Brain Natriuretic peptide (NT-proBNP), a risk marker of CVD, has been shown to be elevated in PHPT patients, indicating that continuously high concentrations of PTH affect the heart. Therefore the aim of this study was to investigate whether teriparatide treatment is associated with changes in plasma NT-proBNP.
Original languageEnglish
JournalScandinavian Journal of Clinical & Laboratory Investigation
Issue number7
Pages (from-to)518-22
Number of pages5
Publication statusPublished - 2012

ID: 48444484